Success Metrics

Completion Rate
0%(0/1)
Active Trials
1(33%)
Terminated
1(33%)

Phase Distribution

Ph phase_1
2
67%
Ph phase_2
1
33%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Terminated(1)
Other(1)

Detailed Status

Suspended1
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (66.7%)
Phase 21 (33.3%)

Trials by Status

suspended133%
recruiting133%
terminated133%

Recent Activity

1 active trials
Showing 3 of 3
recruitingphase_1

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

NCT05187182
suspendedphase_1

A Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases

NCT05669352
terminatedphase_2

Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948

NCT05178342

Clinical Trials (3)

Showing 3 of 3 trials
NCT05187182Phase 1

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

Recruiting
NCT05669352Phase 1

A Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases

Suspended
NCT05178342Phase 2

Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3